By Counterforce Health Team in Onivyde (irinotecan liposome) —

How to Get Onivyde (Irinotecan Liposome) Covered by Humana in New York: Prior Authorization Guide and Appeals Process

Quick Answer: Getting Onivyde Covered by Humana in New York

Onivyde (irinotecan liposome) is covered by Humana Medicare Advantage for pancreatic cancer but requires prior authorization. Your fastest path to approval: Have your oncologist submit a complete PA request with diagnosis, ECOG performance status (0-1), prior therapy history, and planned regimen (NALIRIFOX or post-gemcitabine combo). If denied, you have 65 days to appeal through Medicare's process, not New York's external review system. Start today by confirming your oncologist is in-network and gathering your complete treatment history.

Table of Contents

  1. Humana's Coverage Policy Overview
  2. Medical Necessity Requirements
  3. Prior Authorization Process
  4. Step Therapy and Exceptions
  5. Quantity Limits and Administration
  6. Required Documentation
  7. Appeals Process in New York
  8. Common Denial Reasons and Solutions
  9. Cost Considerations
  10. When to Escalate

Coverage Policy Overview

Humana covers Onivyde (irinotecan liposome) as a Medicare Part B drug for pancreatic cancer treatment. The medication is administered intravenously in clinical settings and billed under J-code J9205. Coverage applies to both HMO and PPO Medicare Advantage plans, but requirements vary slightly.

Plan Type Differences

HMO Plans: Your oncologist must be in Humana's network, and you'll need a referral from your primary care physician. PPO Plans: Offer more flexibility with out-of-network providers but at higher out-of-pocket costs.

Note: Onivyde is not covered under Medicare Part D or dispensed through specialty pharmacies. It's administered and billed through your oncologist's office or outpatient hospital.

Medical Necessity Requirements

Humana requires specific clinical criteria to establish medical necessity for Onivyde coverage:

FDA-Approved Indications

  • First-line metastatic pancreatic adenocarcinoma: NALIRIFOX regimen (approved February 2024)
  • Second-line treatment: Post-gemcitabine therapy in combination with 5-FU and leucovorin

Performance Status Requirements

  • ECOG Performance Status 0-1 (fully active or restricted in strenuous activity only)
  • Good biliary drainage and adequate nutritional intake
  • ECOG 2 may be acceptable in select cases with fluorouracil/leucovorin combination

Organ Function Criteria

Parameter Requirement
Absolute Neutrophil Count ≥ 1,500 cells/mm³
Platelet Count ≥ 100,000 cells/mm³
Hemoglobin ≥ 10 g/dL
Total Bilirubin ≤ 1.5x upper limit of normal
Age ≥ 18 years

Prior Authorization Process

Step-by-Step: Fastest Path to Approval

  1. Verify Network Status (Day 1)
    • Confirm your oncologist is in Humana's network using their provider directory
    • For HMO plans, obtain PCP referral
  2. Gather Documentation (Days 1-2)
    • Pathology report confirming pancreatic adenocarcinoma
    • Current ECOG performance status assessment
    • Recent lab results (within 30 days)
    • Prior therapy history and outcomes
  3. Submit PA Request (Day 3)
    • Oncologist submits Coverage Determination Form
    • Include all supporting clinical documentation
    • Submit via Humana provider portal or fax
  4. Track Your Request (Days 4-30)
    • Standard review takes up to 30 days
    • Expedited review available for urgent cases (72 hours)
    • Follow up if no response within expected timeframe

Required Forms and Submission

Your oncologist must complete Humana's Coverage Determination Form with detailed medical necessity documentation. The form should include:

  • Patient demographics and plan information
  • Diagnosis with ICD-10 codes
  • Planned treatment regimen and duration
  • Clinical rationale with supporting evidence

Step Therapy and Exceptions

Humana may require step therapy for certain regimens, meaning you must try other treatments first. However, exceptions are available:

Medical Exception Pathways

  • Clinical contraindication to preferred agents
  • History of treatment failure with required medications
  • Documented intolerance to step therapy drugs
  • Urgent clinical need preventing delays

Documenting Exceptions

When requesting step therapy exceptions, include:

  • Specific contraindications with clinical rationale
  • Previous treatment records showing failure or intolerance
  • Peer-reviewed literature supporting alternative approach
  • Physician attestation of medical necessity

Quantity Limits and Administration

Dosing and Frequency Limits

  • Maximum 30-day supply per authorization
  • Administered every 2 weeks as part of combination regimen
  • Quantity based on body surface area and planned cycles

NALIRIFOX Regimen Dosing

  • Irinotecan liposome: 50 mg/m² IV over 90 minutes
  • Administered with oxaliplatin, 5-FU, and leucovorin
  • Requires coordination of all combination components

Required Documentation

Clinical Documentation Checklist

Essential Documents:

  • Pathology report with pancreatic adenocarcinoma diagnosis
  • Current ECOG performance status (within 30 days)
  • Complete blood count and comprehensive metabolic panel
  • Prior therapy history and response documentation
  • Treatment plan with planned number of cycles

Supporting Evidence:

  • Relevant imaging studies
  • Multidisciplinary team recommendations
  • Patient consent for treatment
  • Baseline organ function assessments

Clinician Corner: Medical Necessity Letter

Key Elements to Include:

  1. Problem Statement: Metastatic pancreatic adenocarcinoma with specific staging
  2. Prior Treatments: Document previous therapies, responses, and reasons for discontinuation
  3. Clinical Rationale: Why Onivyde is appropriate for this patient's situation
  4. Guideline Support: Reference NCCN guidelines and FDA approval data
  5. Monitoring Plan: How you'll assess response and manage toxicities

Appeals Process in New York

Important Limitation for Medicare Beneficiaries

Medicare patients are NOT eligible for New York State's external appeal process through the Department of Financial Services. Instead, you must use Medicare's standard appeals process.

Medicare Appeals Timeline

Appeal Level Timeframe Process
Initial Appeal 65 days from denial File with Humana directly
Humana Decision 7 calendar days Written notice provided
Further Appeals Varies Through Medicare system

Filing Your Appeal

  1. Contact Humana Member Services: Call the number on your insurance card
  2. Submit Written Appeal: Include denial letter and supporting documentation
  3. Request Expedited Review: Available for urgent medical situations
  4. Follow Up: Track your appeal status through Humana's member portal
From Our Advocates: We've seen many Onivyde denials overturned when the appeal includes comprehensive documentation of prior therapy failures and clear clinical rationale for the specific regimen. The key is providing complete, organized evidence that directly addresses the denial reason.

Common Denial Reasons and Solutions

Denial Reason Solution Strategy
Off-label use Provide FDA approval documentation for NALIRIFOX regimen
Inadequate performance status Submit current ECOG assessment with clinical justification
Missing prior therapy documentation Gather complete treatment history with outcomes
Combination not authorized Submit evidence for complete regimen approval
Quantity limits exceeded Provide dosing calculations and treatment plan

Sample Appeal Language

"This patient has metastatic pancreatic adenocarcinoma with ECOG performance status 1 and adequate organ function. The NALIRIFOX regimen containing Onivyde was FDA-approved in February 2024 based on superior overall survival versus standard care in the NAPOLI 3 trial. Prior therapy with [specific regimen] resulted in [documented outcome], making this FDA-approved combination the appropriate next step per NCCN guidelines."

Cost Considerations

Medicare Coverage Details

  • Part B Coverage: 20% coinsurance after deductible
  • Annual Out-of-Pocket Maximum: Varies by plan
  • Specialty Tier: Not applicable (Part B drug)

Financial Assistance Options

  • Manufacturer Support: Check Onivyde.com for patient assistance programs
  • Medicare Extra Help: Low-income subsidy program
  • State Programs: New York may offer additional assistance (verify with local resources)

When to Escalate

Internal Escalation Steps

  1. Peer-to-Peer Review: Request physician-to-physician discussion
  2. Medical Director Review: Appeal to plan's medical director
  3. Expedited Processing: For urgent clinical situations

External Resources

While Medicare patients cannot use New York's external appeal system, you can:

  • Contact Medicare: 1-800-MEDICARE for guidance
  • File Complaints: With Medicare if Humana violates procedures
  • Seek Advocacy: Community Health Advocates at 888-614-5400

For patients with non-Medicare coverage, Counterforce Health helps streamline the prior authorization and appeals process by analyzing denial letters, identifying coverage gaps, and drafting evidence-backed appeals that address payer-specific requirements. Their platform transforms insurance denials into targeted rebuttals using the right clinical evidence and procedural requirements.

Frequently Asked Questions

How long does Humana's prior authorization take for Onivyde? Standard review takes up to 30 days, with expedited review available in 72 hours for urgent cases.

What if Onivyde is denied as not medically necessary? File an appeal within 65 days with comprehensive clinical documentation, including ECOG status, prior therapy failures, and FDA approval evidence.

Can I get Onivyde if I'm ECOG performance status 2? Possibly, depending on the specific regimen and clinical circumstances. Your oncologist should provide detailed justification for the exception.

Does step therapy apply to first-line NALIRIFOX? This varies by plan. The FDA approval for first-line use may support exceptions to step therapy requirements.

What happens if my oncologist is out-of-network? PPO plans offer out-of-network coverage at higher costs. HMO plans require in-network providers unless you obtain prior authorization for out-of-network care.

How do I track my prior authorization status? Use Humana's member portal or call member services. Your oncologist's office can also check status through the provider portal.

Sources and Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage decisions depend on individual circumstances and plan details. Always verify current requirements with Humana and consult your healthcare provider for medical decisions. For personalized assistance with prior authorizations and appeals, Counterforce Health offers specialized support for patients and clinicians navigating insurance coverage for specialty medications.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.